Gedeon Richter to Acquire Mayne Pharma
Hungarian drugmaker agrees to buy all of Mayne Pharma at $6.40 per share, subject to shareholder approval.
Updated on Nov. 17, 2026 in Healthcare

Mayne Pharma has entered a scheme implementation deed under which Hungarian multinational Gedeon Richter would acquire a 100% stake in the company for $6.40 per share. The scheme is fully funded and remains subject to shareholder approval and completion of Mayne Pharma's previously announced sale of its international business segment to Evaris Pharma.
Why it matters
The offer carries a 99.4% premium to Mayne Pharma's closing price on 16 November and a 124% premium to its 30-day volume weighted average price. Mayne Pharma's board unanimously recommends that shareholders vote in favour of the scheme in the absence of a superior proposal.
The $6.40 per share offer equals a 99.4% premium to Mayne Pharma's 16 November closing price and a 124% premium to its 30-day volume weighted average price. The extraction does not state the total value of the transaction or the date of the scheme meeting.
The players
Gedeon Richter
Gedeon Richter is a Hungarian multinational drugmaker and the proposed acquirer of Mayne Pharma.
Mayne Pharma
Mayne Pharma is the target company of the proposed scheme, whose board has unanimously recommended the offer to shareholders.
Evaris Pharma
Evaris Pharma is the buyer of Mayne Pharma's international business segment, a sale that must complete before the scheme can proceed.
The details
Gedeon Richter entered a scheme implementation deed with Mayne Pharma under which it would acquire 100% of the company. The scheme is subject to customary conditions, including shareholder approval at the scheme meeting, and is conditional on completion of Mayne Pharma's sale of its international business to Evaris Pharma.
Timeline
16 November: Closing price of Mayne Pharma shares used as the basis for the offer premium.
Market Landscape
The acquisition is structured around Mayne Pharma's earlier decision to sell its international business to Evaris Pharma, so Gedeon Richter's bid depends on that divestiture completing first. The deal therefore reflects a sequence in which the target first reshapes its portfolio before a buyer takes control of the remaining company.
Shareholders of Mayne Pharma would receive $6.40 per share in cash if the scheme is approved and completed. Customers and patients are not directly affected by the acquisition terms described in the extraction, which concern ownership of the company.
The takeaway
Shareholders weighing the scheme should note that the offer's value depends on both shareholder approval and the completion of the Evaris Pharma sale, so the premium is not yet assured. Watching the scheme meeting outcome and the status of the divestiture will show whether the deal proceeds.
Further reading
For more on deals of this kind, see the Healthcare section.







